Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 9/20 | 0.46 |
| ▸ | CCKAR | P32238 | 3/20 | 0.41 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.41 |
| ▸ | NOTCH3 | Q9UM47 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7552301 | 1.00 | CCKBR (0.46) | CCKBRCCKARNOTCH1NOTCH3NSD2 | |
| SCHEMBL18324100 | 0.85 | NOTCH1 (0.52) | NOTCH1NOTCH3NSD2BCHEDAO | |
| SCHEMBL15608321 | 0.85 | NOTCH1 (0.52) | NOTCH1NOTCH3NSD2BCHEDAO | |
| SCHEMBL15629464 | 0.85 | NOTCH1 (0.52) | NOTCH1NOTCH3NSD2BCHEDAO | |
| SCHEMBL7544945 | 0.85 | CCKBR (0.41) | CCKBRCCKARNOTCH1NOTCH3DAO | |
| SCHEMBL7544940 | 0.85 | CCKBR (0.41) | CCKBRCCKARNOTCH1NOTCH3DAO | |
| SCHEMBL15623736 | 0.84 | NOTCH1 (0.46) | CCKBRCCKARNOTCH1NOTCH3NSD2 | |
| SCHEMBL15628179 | 0.84 | NOTCH1 (0.46) | CCKBRCCKARNOTCH1NOTCH3NSD2 | |
| SCHEMBL7543703 | 0.82 | CCKBR (0.43) | CCKBRCCKAR | |
| SCHEMBL7543698 | 0.82 | CCKBR (0.43) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-05 | — | — | US | disclosed |
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | disclosed |
| US-6291452-B1 | CHOLECYSTOKININ ANTAGONISTS. | FUJISAWA PHARMACETICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0934282-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015535-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | CCKBR 2/4885CCKAR 1/4885NOTCH1 3631/4885 |
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | CCKBR 2/4885CCKAR 1/4885NOTCH1 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.